ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

3-AP in Treating Patients With Advanced Prostate Cancer

This study is no longer recruiting patients.

Sponsored by: Vion Pharmaceuticals
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have advanced prostate cancer that has been previously treated with hormone therapy.

Condition Treatment or Intervention Phase
recurrent prostate cancer
stage IV prostate cancer
 Drug: 3-AP
 Procedure: chemotherapy
Phase II

MedlinePlus related topics:  Prostate Cancer

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of 3-AP in Patients With Advanced Prostate Cancer

Further Study Details: 

OBJECTIVES:

OUTLINE: This is a multicenter study.

Patients receive 3-AP IV over 2 hours on days 1-4. Treatment repeats every 2 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.

Patients are followed every 2-3 months for up to 1 year.

PROJECTED ACCRUAL: Approximately 13-27 patients will be accrued for this study.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

PATIENT CHARACTERISTICS: Age

Performance status

Life expectancy

Hematopoietic

Hepatic

Renal

Cardiovascular

Pulmonary

Other

PRIOR CONCURRENT THERAPY: Biologic therapy

Chemotherapy

Endocrine therapy

Radiotherapy

Surgery

Other


Location Information


California
      UCSF Comprehensive Cancer Center, San Francisco,  California,  94115,  United States

Florida
      H. Lee Moffitt Cancer Center and Research Institute, Tampa,  Florida,  33612-9497,  United States

Study chairs or principal investigators

Mario Sznol, MD,  Study Chair,  Vion Pharmaceuticals   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000269675; VION-CLI-024; MCC-13110; MCC-IRB-100798
Record last reviewed:  June 2004
Record first received:  February 5, 2003
ClinicalTrials.gov Identifier:  NCT00054015
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-10-22
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act